Why the study?
Does cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) reduce all-cause mortality compared to cardiac resynchronization therapy with pacemaker (CRT-P) in patients with heart failure and severely reduced LV function?
Does cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) reduce all-cause mortality compared to cardiac resynchronization therapy with pacemaker (CRT-P) in patients with heart failure and severely reduced LV function?
CRT-D provides a significant mortality benefit over CRT-P in heart failure patients with ischemic cardiomyopathy, but not in those with non-ischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
CRT-D was associated with lower mortality only in ischemic cardiomyopathy; leaves open etiology-specific benefit and does not support practice change.
Kutyifa et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: